Berkman S A, Lee M L, Gale R P
UCLA School of Medicine.
Ann Intern Med. 1990 Feb 15;112(4):278-92. doi: 10.7326/0003-4819-112-4-278.
To ascertain the activity of intravenous immunoglobulin in a wide range of diseases.
English-language literature search using MEDLINE (1982 to 89), review of meeting reports, and extensive hand searching of bibliographies of identified articles.
All identified articles.
Study quality and specific descriptive information concerning population, intervention, and outcome measurements were assessed.
There have been few controlled, randomized trials of intravenous immunoglobulin. Available data suggest efficacy in persons with primary immune deficiency, premature infants at risk for group B streptococcus infection, patients with Kawasaki disease, transplant recipients at risk for cytomegalovirus infection, patients with idiopathic thrombocytopenic purpura, and selected patients with chronic lymphocytic leukemia. Data are also favorable concerning the use of intravenous immunoglobulin in some other autoimmune disorders, but randomized trials are needed. Interesting areas for future study include the acquired immunodeficiency syndrome (AIDS), multiple myeloma, and lymphomas. Risks of intravenous immunoglobulin are minimal.
Intravenous immunoglobulin is safe and effective in treating several human diseases. Additional randomized trials are needed.
确定静脉注射免疫球蛋白在多种疾病中的活性。
使用MEDLINE（1982年至1989年）进行英文文献检索，查阅会议报告，并广泛手工检索已识别文章的参考文献。
所有已识别的文章。
评估研究质量以及有关人群、干预措施和结局测量的具体描述性信息。
静脉注射免疫球蛋白的对照随机试验很少。现有数据表明，其对原发性免疫缺陷患者、有感染B组链球菌风险的早产儿、川崎病患者、有感染巨细胞病毒风险的移植受者、特发性血小板减少性紫癜患者以及部分慢性淋巴细胞白血病患者有效。在其他一些自身免疫性疾病中使用静脉注射免疫球蛋白的数据也较为有利，但仍需要进行随机试验。未来研究的有趣领域包括获得性免疫缺陷综合征（艾滋病）、多发性骨髓瘤和淋巴瘤。静脉注射免疫球蛋白的风险极小。
静脉注射免疫球蛋白在治疗多种人类疾病方面安全有效。需要进行更多的随机试验。
